GlassScriptPhysician profile
Kathryn Okeeffe
NPI 1023012788
$496.21
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $20.05 · 2021: $14.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156.45 | 2019 | |
| Astellas Pharma US INC | $75.25 | 2019-2020 | |
| Therapeuticsmd, INC. | $41.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.06 | 2019 | |
| Allergan, INC. | $33.20 | 2019 | |
| Novo Nordisk INC | $31.80 | 2019 | |
| Ethicon US, LLC | $30.35 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.32 | 2019 | |
| Pfizer INC. | $25.51 | 2019 | |
| Ge Healthcare | $14.28 | 2021 | |
| Amgen INC. | $13.91 | 2019 | |
| Merck Sharp & Dohme LLC | $12.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Okeeffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.